SCHEMBL7110764

SCHEMBL7110764

CCOP(=O)(CN)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOX1 Q06278 1/20 0.60
ACHE P22303 1/20 0.51
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CA2 P00918 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KCNH2 Q12809 1/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA4 P22748 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.43
NR1I2 O75469 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL779739 0.84 AOX1 (0.64) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL28068172 0.82 AOX1 (0.62) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL9340193 0.82 AOX1 (0.62) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL2521329 0.81 AOX1 (0.60) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL5488235 0.81 AOX1 (0.70) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL5671313 0.81 AOX1 (0.60) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL5002504 0.81 AOX1 (0.60) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL7916451 0.79 AOX1 (0.58) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL27925108 0.78 AOX1 (0.66) AOX1ACHEMEN1KMT2ANPSR1
SCHEMBL2515116 0.78 AOX1 (0.66) AOX1ACHEMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives THERAPHARM GMBH (CH) 2008-12-18 US disclosed
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives THERAPHARM GMBH (CH) 2008-12-18 US disclosed
WO-2003000011-A2 NOVEL PYRIDOPYRIMIDINES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives POLI, PARP1, DHPS AOX1 1037/4885ACHE 3917/4885MEN1 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.